Clinical trial
Phase II Trial of Preoperative Therapy With Gefitinib and Chemotherapy in…
NCT00239343 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00239343 |
|---|---|
| Title | Phase II Trial of Preoperative Therapy With Gefitinib and Chemotherapy in Patients With ERneg Breast Cancer |
| Official title | Randomised Placebo-controlled Phase II Trial of Preoperative Therapy With Gefitinib (Iressa®/ZD1839) and Epirubicin-Cyclophosphamide in Patients With Primary Operable (T2-T3) Oestrogen Receptor Negative Breast Cancer |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | gefitinib |
| Enrollment | 160 |
| Start date | Oct 1, 2004 |
| Primary completion | May 1, 2007 |
| Completion | May 1, 2007 |
| First posted | Oct 17, 2005 |
| Last update posted | Jan 27, 2011 |
| Countries | Denmark, Norway, Sweden |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: